Refractory cancers
that defy research…

Meet a radical new way
of conducting clinical trials

Industry

Our fast-tracked molecular and genomic screening and patient enrolment from the entire nation are increasing clinical trial efficiency and reducing costs.

cancer meets its match

The approach to clinical trials is changing

video_icon

Why work with Omico?

1

Make your trials cheaper and faster to run

2

Get access to 25,000 screened patients

3

Identify the right patients and the right trials

4

Draw on the knowledge and expertise of our network

Our Purpose

As a national, independent not-for-profit organisation, supported by public-private  funding, Omico promotes genomic and molecular screening and precision medicine, to…

  • Stimulate research into prevention, diagnosis and better management of cancers, particularly those with most unmet need
  • Accelerate transition from discovery to clinical application
  • Improve patient access to next-generation cancer therapies
  • Help set new standards of cancer care

Our People

Omico provides a single point of access to over…

  • 25 million Australians
  • 20,000 new cancer patients who are seen each year by our network
  • 1,500 basic and clinical researchers
  • A national network of key opinion leaders in oncology

Our Strengths

We provide access to…

  • An established molecular signal-seeking ‘live’ drug development platform
  • High throughput ‘real time’ matching of patients to biomarker directed studies
  • Opportunities for efficient, innovative and effective trial design, recruitment and completion
  • Biospecimen-rich correlative science and intellectual partnerships

Let’s work together.


Get in touch to advance research together

Our Progress

16,308 Patients Screened
849 Referring Clinicians
9,143 Patients with a treatment recommendation
1,506 Patients accessing a matched therapy

The Omico advantage

Omico is proactively screening thousands of patients with comprehensive genomic profiling to streamline clinical trial enrolment and save costs.

Standard biomarker screening

Traditionally, biomarker screening is performed in each individual clinical trial. This inefficient method contributes significant costs to running a clinical trial, costing in the region of AUD $10M to identify 200 trial participants.

$500
per test
$50,000
per patient identified
200
specific biomakers per AUD $10M

Comprehensive genomic profiling

CGP is a next-generation screening approach that looks for hundreds of cancer biomarkers at the same time. This more efficient method costs in the region of AUD $10 M to identify 400 trial participants for multiple clinical trials, a significant cost saving.

$2,500
per test
$25,000
per patient identified
400
per patient identified

Meet your clinical trial objectives sooner and for a lower cost with Omico.

Our work

Finding new treatment paths for difficult-to-treat cancers

Omico’s landmark Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) aims to open up new options for patients with difficult-to-treat, advanced and metastatic cancers.

Matching patients to biomarker-led clinical trials

Through our Cancer Screening Project (CaSP) we’re performing comprehensive genomic profiling for cancer patients with unmet clinical need to match them to clinical trials or other care pathways.

Matching molecular changes to targeted therapy

Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy.

Identifying genetic basis of cancer risk

We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.

Improving surveillance of multi-organ cancer

Our Surveillance study in Multi-Organ Cancer-prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high risk of multi-organ cancer.

Who we work with

client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo
client-logo

Work with Omico to improve the cost and efficiency of your clinical trials

Let’s connect